Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY4167586
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Administration
- Intravenous, Subcutaneous
01
Overview
LY4167586 is an investigational drug being developed by Eli Lilly and Company for the treatment of obesity and overweight. It is currently in Phase 1 clinical development, where its safety, tolerability, pharmacokinetics, and pharmacodynamics are being evaluated in healthy participants with obesity or overweight. The drug is administered either subcutaneously or intravenously. While its exact molecular target and mechanism of action have not been publicly disclosed, it is designed as a novel therapeutic approach to weight management.
Beyond the preview
Go deeper on LY4167586.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY4167586.